An independent appraisal committee voted that evidence is not adequate to demonstrate a superior net health benefit for ublituximab when compared to other monoclonal antibodies. Analyses suggest ublituximab and all currently available monoclonal antibodies labeled for MS would achieve common thresholds for cost-effectiveness if priced between $16,500- $34,900 per year, a range far lower than current market prices net of all rebates. Payers should ensure that savings from lower-cost biosimilars and generic formulations are shared with patients through the alignment of copay and coinsurance charges.

Final Documents

Jon Campbell, PhD, MS, ICER’s Senior Vice President of Health Economics stated:

“Multiple sclerosis is a burdensome condition, and individuals with MS manage declining function and neurologic symptoms such as weakness, fatigue, vision changes, pain, and balance problems for the rest of their lives.

In this report, ICER focused primarily on evaluating the comparative effectiveness of currently available monoclonal antibody treatments, including the recently-approved agent ublituximab, and other first line disease modifying therapies (DMTs). All assessed DMTs demonstrate clinical benefits versus placebo, but there was insufficient evidence to differentiate between the benefit of ublituximab and other monoclonal antibodies.  Our analysis also found that monoclonal antibodies would need to be priced considerably lower than they are now to meet traditional standards for cost-effectiveness.”

For questions or to request a Spanish translated Report-at-a-Glance for this assessment, please contact

View the Key Stakeholder List.